Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

This activity was originally presented live at Asembia's AXS25 Summit in Las Vegas, Nevada on April 28, 2025.

Program Description
Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a significant clinical and economic burden, characterized by substantial health care resource utilization, reduced quality of life due to bothersome symptoms and common comorbidities, and ongoing challenges in optimizing patient management despite current treatments. Limitations of current strategies, including surgery, and the risks associated with systemic corticosteroids highlight a critical unmet need for more targeted therapies. Biologics are increasingly being used in CRSwNP to improve patient outcomes and reduce disease burden. Despite being reserved for treatment after nasal corticosteroids and surgery failure, recent studies support their use in patients with CRSwNP and various comorbidities. Specialty pharmacists play a crucial role in this evolving landscape by reviewing health care utilization, reducing direct and indirect costs, ensuring access through patient support programs, and improving patient quality of life. This session will examine opportunities for specialty pharmacists to engage patients in their care and maximize benefits of biologic therapies for CRSwNP. In addition to the clinical data and guidelines surrounding approved and emerging biologics, this session will equip pharmacists with practical skills necessary for early patient identification, seamless biologic initiation, thorough counseling, adherence monitoring, and proactive management of this complex condition to optimize outcomes for patients and reduce the overall impact of CRSwNP.

Target Audience: Managed care and specialty pharmacists

Type of Activity: Application
Release date: May 6, 2025
Expiration date: May 6, 2026
Learner level: Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain how biologic therapy addresses immune dysregulation and inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP)
• Analyze current gaps in management of CRSwNP and the role of approved and emerging biologic therapies
• Identify counseling pearls on biologic utilization in CRSwNP, including administration, selection, and access

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-125-H01-P. The activity is available for CE credit through May 6, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Jay Lieberman, MD, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: DBV Pharmaceuticals, Areteia Therapeutics
Consultant: AbbVie Inc; Amgen Inc; Celldex Therapeutics; ALK; Bayer AG; Genentech, Inc; Novartis AG

Matthew Greenhawt, MD, MBA, MSc, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: Asthma and Allergy Foundation of America
Consultant: Aquestive Therapeutics, Inc
Medical Advisory Board: DBV Technologies; Takeda Pharmaceutical Company Limited; Grifols, S.A.; Nutricia; Novartis AG; Aquestive Therapeutics, Inc; Allergy Therapeutics PLC; AstraZeneca; ALK; Bryn Pharma; Genentech, Inc; and Prota Therapeutics
Speakers Bureau: ARS Pharmaceuticals Operations, Inc; Genentech, Inc.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Shannon M. Rotolo, PharmD, BCPS

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms